Miguel Cantalejo-Díaz , José M. Ramia , Iñaki Álvarez-Busto , Balint Kokas , Gerardo Blanco-Fernández , Elena Muñoz-Forner , Attila Oláh , Eva Montalvá-Orón , Víctor López-López , Fernando Rotellar , Hasan Eker , Arjen Rijken , Mikel Prieto-Calvo , Fabrizio Romano , Paola Melgar , Nikolaos Machairas , Semra Demirli Atici , Maria Jesús Castro-Santiago , Mickaël Lesurtel , Michal Skalski , Mario Serradilla-Martín
{"title":"乳腺癌肝转移手术后的长期疗效：欧洲回顾性快照研究（LIBREAST 研究）。","authors":"Miguel Cantalejo-Díaz , José M. Ramia , Iñaki Álvarez-Busto , Balint Kokas , Gerardo Blanco-Fernández , Elena Muñoz-Forner , Attila Oláh , Eva Montalvá-Orón , Víctor López-López , Fernando Rotellar , Hasan Eker , Arjen Rijken , Mikel Prieto-Calvo , Fabrizio Romano , Paola Melgar , Nikolaos Machairas , Semra Demirli Atici , Maria Jesús Castro-Santiago , Mickaël Lesurtel , Michal Skalski , Mario Serradilla-Martín","doi":"10.1016/j.suronc.2024.102129","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Breast cancer (BC) is the most common malignant tumor in women. Between 20 % and 30 % of patients develop metastases from BC, 50 % of them in the liver. The mean survival rate reported in patients with liver metastases from BC (LMBC) ranges from 3 to 29 months. The role of surgery in LMBC is not clearly defined. The objective of the present study was to determine the long-term survival and disease-free survival of patients undergoing surgery for LMBC and to identify the patients who most likely benefit from surgery.</p></div><div><h3>Material and methods</h3><p>This retrospective multicenter cohort study included all consecutive patients undergoing LMBC surgery at the participating European centers from January 1, 2010, to December 31, 2015. The <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> ID is NCT04817813.</p></div><div><h3>Results</h3><p>A hundred women (mean age 52.6 years) undergoing LMBC surgery were included. Five-year disease-free survival was 29 %, and 5-year overall survival was 60 %. Median survival after BC surgery was 12.4 years, and after LMBC surgery, 7 years. Patients with ECOG 1, ASA score I-II, metachronous LMBC, positive hormone receptors, and who had received neoadjuvant and adjuvant hormone treatment obtained the best overall and disease-free survival results.</p></div><div><h3>Conclusions</h3><p>In cases of correct patient selection and as part of a comprehensive onco-surgical strategy, surgery for LMBC improves overall long-term survival. In our series, certain factors were linked to better disease-free and overall survival; consideration of these factors could improve the selection of the best candidates for LMBC surgery.</p></div><div><h3>Clinicaltrials.gov id</h3><p>NCT04817813.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term outcomes after breast cancer liver metastasis surgery: A European, retrospective, snapshot study (LIBREAST STUDY)\",\"authors\":\"Miguel Cantalejo-Díaz , José M. Ramia , Iñaki Álvarez-Busto , Balint Kokas , Gerardo Blanco-Fernández , Elena Muñoz-Forner , Attila Oláh , Eva Montalvá-Orón , Víctor López-López , Fernando Rotellar , Hasan Eker , Arjen Rijken , Mikel Prieto-Calvo , Fabrizio Romano , Paola Melgar , Nikolaos Machairas , Semra Demirli Atici , Maria Jesús Castro-Santiago , Mickaël Lesurtel , Michal Skalski , Mario Serradilla-Martín\",\"doi\":\"10.1016/j.suronc.2024.102129\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Breast cancer (BC) is the most common malignant tumor in women. Between 20 % and 30 % of patients develop metastases from BC, 50 % of them in the liver. The mean survival rate reported in patients with liver metastases from BC (LMBC) ranges from 3 to 29 months. The role of surgery in LMBC is not clearly defined. The objective of the present study was to determine the long-term survival and disease-free survival of patients undergoing surgery for LMBC and to identify the patients who most likely benefit from surgery.</p></div><div><h3>Material and methods</h3><p>This retrospective multicenter cohort study included all consecutive patients undergoing LMBC surgery at the participating European centers from January 1, 2010, to December 31, 2015. The <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> ID is NCT04817813.</p></div><div><h3>Results</h3><p>A hundred women (mean age 52.6 years) undergoing LMBC surgery were included. Five-year disease-free survival was 29 %, and 5-year overall survival was 60 %. Median survival after BC surgery was 12.4 years, and after LMBC surgery, 7 years. Patients with ECOG 1, ASA score I-II, metachronous LMBC, positive hormone receptors, and who had received neoadjuvant and adjuvant hormone treatment obtained the best overall and disease-free survival results.</p></div><div><h3>Conclusions</h3><p>In cases of correct patient selection and as part of a comprehensive onco-surgical strategy, surgery for LMBC improves overall long-term survival. In our series, certain factors were linked to better disease-free and overall survival; consideration of these factors could improve the selection of the best candidates for LMBC surgery.</p></div><div><h3>Clinicaltrials.gov id</h3><p>NCT04817813.</p></div>\",\"PeriodicalId\":51185,\"journal\":{\"name\":\"Surgical Oncology-Oxford\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Surgical Oncology-Oxford\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0960740424000975\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Oncology-Oxford","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960740424000975","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Long-term outcomes after breast cancer liver metastasis surgery: A European, retrospective, snapshot study (LIBREAST STUDY)
Introduction
Breast cancer (BC) is the most common malignant tumor in women. Between 20 % and 30 % of patients develop metastases from BC, 50 % of them in the liver. The mean survival rate reported in patients with liver metastases from BC (LMBC) ranges from 3 to 29 months. The role of surgery in LMBC is not clearly defined. The objective of the present study was to determine the long-term survival and disease-free survival of patients undergoing surgery for LMBC and to identify the patients who most likely benefit from surgery.
Material and methods
This retrospective multicenter cohort study included all consecutive patients undergoing LMBC surgery at the participating European centers from January 1, 2010, to December 31, 2015. The ClinicalTrials.gov ID is NCT04817813.
Results
A hundred women (mean age 52.6 years) undergoing LMBC surgery were included. Five-year disease-free survival was 29 %, and 5-year overall survival was 60 %. Median survival after BC surgery was 12.4 years, and after LMBC surgery, 7 years. Patients with ECOG 1, ASA score I-II, metachronous LMBC, positive hormone receptors, and who had received neoadjuvant and adjuvant hormone treatment obtained the best overall and disease-free survival results.
Conclusions
In cases of correct patient selection and as part of a comprehensive onco-surgical strategy, surgery for LMBC improves overall long-term survival. In our series, certain factors were linked to better disease-free and overall survival; consideration of these factors could improve the selection of the best candidates for LMBC surgery.
期刊介绍：
Surgical Oncology is a peer reviewed journal publishing review articles that contribute to the advancement of knowledge in surgical oncology and related fields of interest. Articles represent a spectrum of current technology in oncology research as well as those concerning clinical trials, surgical technique, methods of investigation and patient evaluation. Surgical Oncology publishes comprehensive Reviews that examine individual topics in considerable detail, in addition to editorials and commentaries which focus on selected papers. The journal also publishes special issues which explore topics of interest to surgical oncologists in great detail - outlining recent advancements and providing readers with the most up to date information.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
